Advertisement

Buy track record

How this insider's open-market purchases have performed
0%
of buys now in profit
0 up · 2 down
Avg return since buy−81.4%
Median return−81.4%
Best trade−81.3%
Worst trade−81.6%
Buys scored2
Average return by holding period — separates good entry timing from riding one long winner
After 1 month +28.9% 100% won · 2 trades
After 3 months −23.5% 0% won · 2 trades
After 6 months −24.7% 0% won · 2 trades
After 12 months −46.5% 0% won · 2 trades
DateCompany90d trendBuy priceValueΔOwn1M3M6M12MTo date
Jan 11, 2022 RLYB $11 $47.9K +1.6% +29.1% −24.0% −25.2% −47.8% −81.6%
Jan 10, 2022 RLYB $10 $55.6K +2.0% +28.8% −22.9% −24.2% −45.2% −81.3%
How this is calculated. We score only open-market purchases (SEC code P) — the buys that carry real signal. Each trade's return is measured from the adjusted closing price on the purchase date to the latest close, accounting for stock splits and dividends. The 1M/3M/6M/12M columns show the same trade's return after each fixed holding period; a dash means that horizon hasn't elapsed yet or isn't priceable. Sales are excluded because insiders sell for many routine reasons. With only 2 scored trades, treat this as a small sample, not a verdict.
Advertisement
Open-market buys
$118K
3 trades
Open-market sells
$18.35M
28 trades
Net flow
−$18.24M
Net selling
Total filings
61
transactions shown

Full transaction history

All Form 4 activity across every company, newest first
View on SEC EDGAR ↗
ALXN
Sell MACKAY MARTIN · EVP & Global Head of R&D · Open-market sale · filed Mar 1, 2016 ΔOwn −2.1%

Mackay Martin sold $138.9K of ALXN, trimming their stake 2%.

−$138.9K
1,000 sh @ $139
ALXN
Sell MACKAY MARTIN · EVP & Global Head of R&D · Open-market sale · filed Feb 8, 2016 ΔOwn −4.5%

Mackay Martin sold $263.3K of ALXN, trimming their stake 4%.

−$263.3K
1,908 sh @ $138
Advertisement
ALXN
Sell MACKAY MARTIN · EVP & Global Head of R&D · Open-market sale · filed Feb 8, 2016 ΔOwn −0.8%

Mackay Martin sold $52.3K of ALXN, trimming their stake 1%.

−$52.3K
362 sh @ $144
ALXN
Sell MACKAY MARTIN · EVP & Global Head of R&D · Open-market sale · filed Feb 8, 2016 ΔOwn −0.9%

Mackay Martin sold $56.5K of ALXN, trimming their stake 1%.

−$56.5K
400 sh @ $141
ALXN
Sell MACKAY MARTIN · EVP & Global Head of R&D · Open-market sale · filed Feb 8, 2016 ΔOwn −2.4%

Mackay Martin sold $146.5K of ALXN, trimming their stake 2%.

−$146.5K
1,043 sh @ $140
ALXN
Sell MACKAY MARTIN · EVP & Global Head of R&D · Open-market sale · filed Aug 5, 2015 ΔOwn −22%

Mackay Martin sold $3.37M of ALXN, trimming their stake 22%.

−$3.37M
17,100 sh @ $197
ALXN
Sell MACKAY MARTIN · EVP & Global Head of R&D · Open-market sale · filed Aug 5, 2015 ΔOwn −30%

Mackay Martin sold $3.44M of ALXN, trimming their stake 30%.

−$3.44M
17,518 sh @ $196
ALXN
Sell MACKAY MARTIN · EVP & Global Head of R&D · Open-market sale · filed Aug 5, 2015 ΔOwn −21%

Mackay Martin sold $1.73M of ALXN, trimming their stake 21%.

−$1.73M
8,882 sh @ $195
ALXN
Sell MACKAY MARTIN · EVP & Global Head of R&D · Open-market sale · filed May 22, 2015 ΔOwn −11%

Mackay Martin sold $650.3K of ALXN, trimming their stake 11%.

−$650.3K
4,056 sh @ $160
ALXN
Sell MACKAY MARTIN · EVP & Global Head of R&D · Open-market sale · filed Mar 3, 2015 ΔOwn −1.0%

Mackay Martin sold $66.7K of ALXN, trimming their stake 1%.

−$66.7K
370 sh @ $180
ALXN
Sell MACKAY MARTIN · EVP & Global Head of R&D · Open-market sale · filed Feb 12, 2015 ΔOwn −5.5%

Mackay Martin sold $340.6K of ALXN, trimming their stake 6%.

−$340.6K
1,990 sh @ $171
ALXN
Sell MACKAY MARTIN · EVP & Global Head of R&D · Open-market sale · filed Feb 12, 2015 ΔOwn −5.6%

Mackay Martin sold $337.4K of ALXN, trimming their stake 6%.

−$337.4K
1,907 sh @ $177
ALXN
Sell MACKAY MARTIN · EVP & Global Head of R&D · Open-market sale · filed Nov 4, 2014 ΔOwn −28%

Mackay Martin sold $1.8M of ALXN, trimming their stake 28%.

−$1.8M
9,375 sh @ $192
ALXN
Sell MACKAY MARTIN · EVP & Global Head of R&D · Open-market sale · filed Jun 13, 2014 ΔOwn −10%

Mackay Martin sold $839K of ALXN, trimming their stake 10%.

−$839K
5,058 sh @ $166
ALXN
Sell MACKAY MARTIN · EVP & Global Head of R&D · Open-market sale · filed Jun 13, 2014 ΔOwn −36%

Mackay Martin sold $2.65M of ALXN, trimming their stake 36%.

−$2.65M
15,949 sh @ $166
ALXN
Sell MACKAY MARTIN · EVP & Global Head of R&D · Open-market sale · filed Jun 13, 2014 ΔOwn −14%

Mackay Martin sold $668.4K of ALXN, trimming their stake 14%.

−$668.4K
3,993 sh @ $167
ALXN
Sell MACKAY MARTIN · EVP & Global Head of R&D · Open-market sale · filed May 15, 2014 ΔOwn −13%

Mackay Martin sold $574.9K of ALXN, trimming their stake 13%.

−$574.9K
3,574 sh @ $161

Frequently asked questions

How is MACKAY MARTIN's win rate calculated?

We take every open-market purchase (SEC code P) we can match to a stock price, then compare the split- and dividend-adjusted price on the purchase date to the most recent close. The win rate is the share of those buys currently trading above the purchase price. Sales and share grants are not scored.

Why are some buys not included in the score?

A purchase is excluded if we can't price it — for example if the ticker is missing from the filing, the company has been delisted, or the security isn't a common stock we can match to market data. Excluded counts are shown next to the scored total.

What do the 1M / 3M / 6M / 12M columns mean?

They show each purchase's return after a fixed holding period — one, three, six, and twelve months from the buy date — using split- and dividend-adjusted prices. This separates good entry timing from simply holding a long-running winner. A dash means that horizon hasn't elapsed yet for that trade, or the stock couldn't be priced at that date.

Does a high win rate mean I should copy this insider?

No. Past performance does not predict future results, sample sizes are often small, and an insider's edge in their own company doesn't transfer to yours. This is context, not a recommendation. InsiderSource is not investment advice.

Where does this data come from?

Trades come from MACKAY MARTIN's SEC Form 4 filings on EDGAR. Prices come from public market data and are split/dividend-adjusted. Always verify against the original filings before acting.